Therefore, drugs such as venetoclax, a selective inhibitor of B-cell lymphoma 2 (BCL-2), which has been used successfully in the treatment of elderly patients with acute myeloid leukemia, may be worthy of further investigation. This evidence concerns the gene BCL2 and acute myeloid leukemia.